Randomized controlled clinical trial on the treatment of Thymosin-a1 vs interferon-α in patients with hepatitis B

Table 1 Responses to treatment at the end of therapy n (%)

	T-a1 (n = 18)	IFN-α (n = 33)	HC (n = 30)
	(after 6 mo of follow-up)
ALT normalization	7 (38.9)	16 (48.5)	5 (16.7)
HBV DNA-negative	10 (55.6)b	22 (66.7)b	2 (6.7)
ALT normal/HBV DNA and HBeAg-negative	6 (33.3)	15 (45.5)b	1 (3.3)

^bP < 0.01, vs HC.

Table 2 Responses to treatment at the end of follow-up n (%)

	T-a1 (n = 18)	IFN-α (n = 33)	HC (n = 30)
	(after 12 mo of follow-up)
ALT normalization	11 (61.1)a	10 (30.3)	3 (10)
HBV DNA-negative	13 (72.2)ab	13 (39.4)b	2 (6.7)
ALT normal/HBV DNA and HBeAg-negative	10 (55.6)ab	9 (27.3)	1 (3.3)

^aP < 0.05, vs IFN-α;

^bP < 0.01, vs HC.